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Abstract   
Statins are first-line agents in patients with dyslipidemia, with established benefits for 
reducing low-density-lipoprotein cholesterol (LDL-C) levels and cardiovascular events. 
However, a considerable number of statin-treated patients do not achieve target LDL-C levels, 
even at maximally tolerated statin doses, or are intolerant to intensive statin therapy. These 
patients can benefit from the addition of a non-statin lipid-lowering agent, and recent 
cholesterol guidelines have placed increased focus on combination lipid-lowering therapy. For 
patients that cannot achieve target treatment goals with statin therapy alone, the addition of 
the cholesterol absorption inhibitor ezetimibe leads to additional LDL-C reductions with good 
tolerability, and reductions in cardiovascular morbidity and mortality. The more recent 
Proprotein Convertase Subtilisin-Like/Kexin Type 9 (PCSK-9) inhibitors can lower LDL-C 
by an additional 45–65% and are also well tolerated with associated cardiovascular outcome 
data. These complementary approaches for LDL-C lowering in statin-treated patients lower 
LDL-C levels beyond that achieved with statin monotherapy. As no threshold level has been 
established below which LDL-C lowering benefits cease to occur, an early combination 
treatment strategy may lead to improved cardiovascular outcomes, particularly in high-risk 
patients. This review will examine the rationale, advantages and potential barriers to 
combination lipid-lowering therapy with reference to current guideline recommendations. 
 
  
 
 
Introduction 
Atherosclerotic cardiovascular disease (ASCVD) remains one of the leading causes of death 
worldwide [1], and high lifelong levels of atherogenic lipoproteins are one of the major risk 
factors. There are many reasons for poor cholesterol control including inappropriate use of 
treatment options, low patient adherence, therapeutic and physician inertia, and deficiencies in 
healthcare systems [2,3]. However, treatments are now available that can lower LDL 
cholesterol levels to below guideline recommended targets (< 55 mg/dl) in almost all patients 
[2,3]. Furthermore, these treatments are backed up by evidence of cardiovascular protection in 
large randomized controlled trials [2,3]. The focus must now be on how to optimize treatment 
by prescribing effective combinations as single pills and tailoring treatment to individual 
patients based on their ASCVD risk profile.  
This review will examine the rationale and evidence for adding ezetimibe and the Proprotein 
Convertase Subtilisin/Kexin type 9 (PCSK-9) inhibitors as second- and third-line treatments, 
respectively, to statins, and in whom these agents should be prescribed in light of recent 
updates to international cholesterol-lowering guidelines. 
The role of LDL-C reduction in cardiovascular events and the current therapeutic 
armamentarium 
The role of elevated levels of atherogenic lipoproteins in the development of ASCVD and its 
clinical manifestations is firmly established. Data from epidemiological studies, genetic 
analyses and randomized clinical trials have provided consistent evidence that high levels of 
these lipids, irrespective of their underlying cause, are strongly associated with ASCVD and 
cardiovascular mortality and that lowering their levels reduces this risk [4]. Recent 
longitudinal data from several observational studies including Framingham Offspring [5], the 
Multinational Cardiovascular Risk Consortium [6] and the Cooper Clinic Longitudinal Study 
[7] have shown that life-long elevations in either low-density lipoprotein cholesterol (LDL-C) 
 
 
or non-high-density lipoprotein cholesterol (non-HDL-C) are associated with significantly 
higher future ASCVD risk compared with individuals with low levels throughout adulthood 
[8].  
Mendelian randomization studies have emerged as a powerful method to examine whether 
associations between exposures and disease outcomes are causal. Thus, for example, 
individuals with favourable mutations in genes such as PSCK-9 have low PCSK-9 levels and 
lifelong low LDL-C levels [9]. Meta-analyses of Mendelian randomization studies have 
demonstrated that the association between long-term exposure to lower LDL-C and the risk of 
ASCVD was approximately log-linear [2-4]. 
A causal role for atherogenic lipids in ASCVD is further implicated by the results of 
numerous landmark randomized clinical trials in a variety of patient populations, which have 
demonstrated that lowering LDL-C with a statin significantly reduces the risk of ASCVD 
events as well as all-cause mortality. Just as for the Mendelian randomization studies, meta-
analyses of the statin trials have confirmed a dose-dependent, approximately log-linear 
relationship between the absolute reduction in LDL-C and the proportional reductions in the 
incidence of coronary and major vascular events [10]. Successive meta-analyses of statin 
trials by the Cholesterol Treatment Trialists’ Collaborators have shown that active treatment 
reduces the risks of major coronary events (myocardial infarction [MI] or death from coronary 
heart disease [CHD]), ischemic strokes, and coronary revascularisations by about one fifth 
(22% - 23%) for each 1 mmol/L reduction in LDL-C [11-12]. The second CTTC meta-
analysis included 26 randomized controlled trials: 21 of statin versus control and five of more 
versus less intensive statin regimens [12]. The results showed that additional reductions in 
LDL-C with more intensive therapy further reduced the incidence of these major vascular 
events and found no significant evidence that intensive lowering of LDL-C produced any 
adverse effects [12]. These results suggest that intensive lowering in high-risk patients may 
 
 
produce additional benefits. However, given that high doses of some statins may be associated 
with a higher risk of myopathy [13,14], these benefits may be more safely achieved by 
combination of standard doses with other LDL-C lowering therapies. 
More recent meta-analyses have also included non-statin lipid-lowering therapies including 
diet, bile acid sequestrants, ileal bypass surgery, ezetimibe and PCSK-9 inhibitors [15-17]. In 
a meta-analysis of 49 clinical trials of over 312 000 participants, Silverman et al showed that 
each 1 mmol (38.7 mg/dL) reduction in LDL-C was associated with reductions in risk of 
major vascular events of 23% for statins and 25% for the non-statin interventions [15]. The 
Silverman et al meta-analysis investigated the entire statin class, without distinguishing the 
different types and doses of statin therapy administered. This has been addressed by Koskinas 
et al, who compared the clinical impact of more intensive versus less intensive LDL-C 
lowering by statin or non-statin medications for secondary prevention in a meta-analysis of 19 
randomized controlled trials including over 152 000 patients [16]. More intensive lowering 
was associated with a 19% greater reduction in major vascular events across the different 
treatments and was more pronounced for statin vs. no statin when compared with either statin 
intensification or addition of a non-statin agent. These findings support current guidelines 
recommending statins (up-titrated to the highest tolerable doses) as first-line treatment for 
LDL-C lowering in patients at very high risk, with the addition of ezetimibe and PCSK-9 
inhibitors as valuable add-on therapies in statin-treated patients requiring additional LDL-C 
lowering [3,8].  
Mechanisms of action and LDL-C lowering efficacy  
In the 2019 ESC/EAS guidelines [3], three main options exist for the management of high 
cholesterol levels: statins, ezetimibe and PCSK-9 inhibitors, with the intensity of the 
intervention depending on the individual’s level of cardiovascular risk.  
 
 
Statins reduce the synthesis of cholesterol in the liver by competitively inhibiting the enzyme 
HMG-CoA reductase (Figure 1). This promotes upregulation of hepatic LDL receptor 
expression, thereby decreasing plasma concentrations of LDL-C as well as other ApoB-
containing lipoproteins. Statins have clinically relevant differences in efficacy and choice of 
individual agent should be dictated by the level of LDL-C reduction required. The following 
range of LDL-C reductions has been reported for the individual statins as monotherapy: 
rosuvastatin, 45-63% (5-40 mg daily); atorvastatin, 26-60% (10-80 mg daily); simvastatin, 
26-47% (10-80 ng daily); lovastatin, 21-42% (10-80 mg daily); Fluvastatin, 22-36% (10-20 
mg daily); pitavastatin, 32-43% (1-4 mg daily); and pravastatin, 22-34% (10-80 mg daily). 
Each doubling of the statin dose yields an additional 6% reduction on average in LDL-C [18]. 
Ezetimibe is a first-in-class selective cholesterol absorption inhibitor that blocks cholesterol 
absorption at the level of the brush border of the intestine without affecting the absorption of 
fat-soluble nutrients (Figure 1) [19]. This reduces the amount of cholesterol delivered to the 
liver, which responds by upregulating LDL receptor expression resulting in increased 
clearance of LDL-C from the blood. Ezetimibe monotherapy is associated with LDL-C 
reductions of approximately 20%. The mechanisms of action of statins and ezetimibe are 
complementary and their coadministration leads to substantial additional reductions in LDL-C 
compared with statin monotherapy. This facilitates the attainment of LDL-C goals and may 
reduce the need for higher statin doses in those patients requiring more rigorous LDL-C 
reductions. 
PCSK-9 inhibitors are human monoclonal antibodies that bind human PCSK-9 with high 
affinity that reduce LDL-C concentrations by decreasing the degradation of LDL receptors 
available for recycling at the hepatocyte cell surface (Figure 1) [20]. Two PCSK-9 inhibitors, 
evolocumab and alirocumab, have been approved for primary and secondary prevention, and 
both substantially reduce LDL-C levels by approximately 50% to 60% [20].  
 
 
The importance of a statin/ezetimibe association 
For high-risk individuals requiring secondary prevention with cholesterol-lowering therapy, 
current guidelines recommend first-line treatment with a high-intensity statin prescribed up to 
the highest tolerated dose [2,3,8]. However, a large proportion of high-risk patients does not 
achieve LDL-C targets even on maximum tolerated dose [21], and around 10%-20% of 
patients on statins suffer some degree of intolerance and require a dose adjustment [22,23]. 
For patients who fail to achieve their LDL‐C target with a maximum tolerated statin dose, 
combination with ezetimibe is recommended as second-line treatment based on the rationale 
that inhibiting the two main sources of cholesterol – synthesis and uptake – will produce more 
effective lipid lowering than targeting synthesis alone. 
Ezetimibe, indeed, acts by interfering with the gastrointestinal cholesterol absorption through 
the inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) [24], a key protein involved in 
cholesterol absorption that is abundantly expressed in the small intestine and liver. Ezetimibe 
in response of the inhibition of NPC1L1 of cholesterol absorption causes a homeostatic 
upregulation of LDL receptors in the liver thus leading to increased clearance of cholesterol 
from the blood [25]. 
Ezetimibe is rapidly glucuronidated in the intestines, and the glucuronide undergoes 
enterohepatic recirculation which causes the long duration of action (22 hours) [26]. 
Ezetimibe is not metabolized by cytochrome P450 enzymes and has a low potential for 
causing clinically significant drug interactions when co-administered with all currently 
available statins [19]. Pooled safety data from four similarly designed trials of ezetimibe (10 
mg) co-administered with statins (10-80 mg) in 2 382 patients with primary 
hypercholesterolemia reported no significant differences in the incidences of laboratory 
(elevated ALT/AST and CK levels) and clinical adverse events including hepatic, muscle, 
hepatitis-, gastrointestinal-, gallbladder-related, and allergic reaction/rash adverse events 
 
 
compared with statin monotherapy [27]. A 2008 meta-analysis of 18 randomized clinical trials 
(n = 14 497) in which combination ezetimibe and statin therapy was compared with statin 
monotherapy confirmed these findings [28].  
Two other issues strongly support the combination therapy: 1) the extreme variability in LDL 
cholesterol lowering response by monotherapy either statins [29] or ezetimibe [30] as 
compared to the lower relative variability  in patients treated with statins + ezetimibe [31];  
and 2)  The complementary mechanisms of action of statins + ezetimibe which provides a 
powerful approach to prevent and treat atherosclerosis [32].  
Numerous randomized controlled studies have confirmed that the combination of a statin with 
add-on ezetimibe has greater cholesterol-lowering efficacy than statin monotherapy, due to 
the synergistic additive effect of simultaneously inhibiting both cholesterol synthesis and 
absorption. A pooled analysis of four similarly designed trials of ezetimibe co-administered 
with a statin (atorvastatin, simvastatin, pravastatin or lovastatin) in 2 382 patients with 
primary hypercholesterolemia showed that ezetimibe combined with the lowest dose of a 
statin was as effective at lowering LDL-C as the highest dose of statin monotherapy [27]. 
These findings have also been confirmed by real-world data from a large retrospective study 
of a US managed-care database, which demonstrated greater efficacy of ezetimibe added to 
simvastatin, atorvastatin, or rosuvastatin monotherapy compared with up-titration of the statin 
monotherapy [33].  
The clinical significance of ezetimibe an add-on to statin therapy was first demonstrated in the 
SHARP trial conducted in 9 270 patients with chronic kidney disease treated with the 
combination of ezetimibe 10 mg plus simvastatin 20 mg [34]. The results of the trial have 
clearly shown that the combination simvastatin – ezetimibe reduced LDL-C by 33 mg/dL 
(0.85 mmol/L) associated with a significant 17% reduction in major atherosclerotic events 
[34]. 
 
 
A second trial IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy 
International Trial) evaluated the efficacy of ezetimibe 10 mg/simvastatin 40 mg versus 
simvastatin 40 mg/placebo for reducing risk of cardiovascular morbidity and mortality in 
patients hospitalized within the preceding 10 days for an acute coronary syndrome (ACS), a 
group at high risk of recurrent cardiovascular events [35]. It was the first study powered for 
clinical outcomes to show a benefit with a non-statin agent when added to a statin. A total of 
18 144 patients from 39 countries were randomized: 9 067 to the combination and 9 077 to 
simvastatin alone. Patients were required to have an LDL-C of 50-125 mg/dL (50-100 mg/dL 
if on prior lipid-lowering therapy) [35]. Exclusions were failure to meet ACS stability criteria, 
current statin treatment more potent than simvastatin 40 mg, creatinine clearance < 30 ml/min 
and active liver disease. The study continued until each patient had been followed up for a 
minimum of 2.5 years and until the target number of events (5 250) was reached. Baseline 
characteristics were similar between the two arms: mean age was 64 years, 25% were female, 
around 27% had type 2 diabetes and 21% a history of prior MI. Over the course of the study, 
up-titration to 80 mg simvastatin was required in 6% of the combination arm and 27% of the 
monotherapy arm. Baseline LDL-C levels were 95 mg/dL in both arms. Reductions in LDL-C 
were observed as early as 1 month and sustained, with mean levels of 54 mg/dL and 70 
mg/dL achieved in the ezetimibe/simvastatin and simvastatin arms, respectively, over a 
median follow-up of 6 years [35].  
The primary efficacy endpoint, a composite of CVD death, major adverse cardiac event 
(nonfatal MI, unstable angina leading to hospitalization, coronary revascularization after day 
30), or nonfatal stroke, was significantly lower in the ezetimibe/simvastatin compared with 
simvastatin arm over the duration of follow-up (32.7% vs. 34.7%, P = 0.02) [35]. Other 
endpoints including MI, stroke, and a composite of cardiovascular death/MI/stroke were all 
significantly lower in the ezetimibe/simvastatin arm; no differences were noted for all-cause 
 
 
mortality, cardiovascular mortality, and need for coronary revascularization [35]. Prespecified 
secondary analyses of IMPROVE-IT have confirmed the benefits of adding ezetimibe to 
simvastatin in both men and women [36], patients with diabetes [37] and the elderly [38], as 
well as the long-term safety and efficacy of achieving very low LDL-C levels (< 30 mg/dL) 1 
month after an ACS [39]. 
Prespecified safety endpoints included abnormal elevations of liver enzyme and creatine 
kinase levels, myopathy, rhabdomyolysis, adverse hepatobiliary events, and cancer. The rates 
of these adverse events were low in IMPROVE-IT and ezetimibe did not increase myopathy 
or transaminitis compared with placebo. There was no increase in the incidence of cancer or 
new-onset type 2 diabetes, and no increase in study-drug discontinuation rates. Importantly, in 
IMPROVE-IT median trial follow-up was 6 years, a duration that is more than adequate to 
identify low frequency adverse events or those appearing after long-term exposure. Over this 
period, the 971 patients who achieved an LDL-C of ≤ 30 mg/dL at 1 month had no excess 
safety concerns, including hemorrhagic stroke or cataract-related adverse events [39].   
In all the trials, the effect of combination with ezetimibe + statin  treatment on cholesterol 
levels was more pronounced in patients with type 2 diabetes than in those without, whereas 
the effect of statin alone did not differ between those with and without type 2 diabetes [35,40-
42].  
Compared with standard statin monotherapy, the combination of statin plus ezetimibe showed 
greater coronary plaque regression, which might be attributed to cholesterol absorption 
inhibition–induced aggressive lipid lowering [43]. This difference translated into a reduced 
risk of ASCVD events in both individual trials [37] and a meta-analysis of randomized 
controlled trials with a statin control arm, which showed that an ezetimibe/statin combination 
was associated with a greater reduction of major adverse cardiovascular events in patients 
with diabetes than in those without [44].  
 
 
Available fixed-dose combinations with ezetimibe 
Based on the above premises, in order to simplify dosing and improve adherence for patients 
taking both agents [45], single-pill formulations (SPC) have been developed for ezetimibe 
combinations with simvastatin, atorvastatin and rosuvastatin. Different formulations of fixed 
combination rosuvastatin/ezetimibe have been developed from a hard gelatine capsule 
containing two unique tablets of the two separate active ingredients to tablet [42]. 
Pharmacokinetics studies for both formulations have demonstrated their bioequivalence in 
terms of AUC and Cmax to concurrent administration of each corresponding individual drugs 
thus supporting their potential clinical use [46]. 
Each of the individual component used in these different combinations has well-characterized 
efficacy and safety profiles that have been studied in randomized controlled trials across 
different comorbid conditions, ages and geographic regions. In Europe, all three combinations 
are indicated as adjunctive therapy to diet for use in patients with homozygous familial 
hypercholesterolemia, and in patients with primary hypercholesterolemia or mixed 
hyperlipidemia, when appropriate.   
The respective lipid-lowering efficacy, in terms of mean percent changes total cholesterol and 
LDL-C levels, of the three combinations is illustrated in Table 1. 
Finally, among newer agents, the prodrug bempedoic acid, when metabolized to the active 
form in the liver, is responsible for the inhibition of ATP citrate lyase (ACL) leading to a 
reduced production of cytosolic acetyl-coenzyme-A, a precursor of the mevalonate pathway 
of cholesterol biosynthesis [47]. Recent studies have demonstrated that bempedoic acid is a 
safe and effective lipid-lowering agent and may be a suitable alternative in statin-intolerant 
patients [48]. Fixed combination of bempedoic acid with ezetimibe reduced LDL-C up to − 
41% [49].  
 
 
 
What are the benefits of adding a PCSK-9 inhibitor to a statin/ezetimibe combination? 
The incremental LDL-C lowering benefit of adding ezetimibe to statins and the demonstration 
that there is no LDL-C threshold for clinical benefit have paved the way for the addition of 
further lipid-lowering agents as triple therapy to achieve even greater reductions in LDL-C. 
This has come in the form of the anti-PCSK-9 monoclonal antibodies (PCSK9-inhibitors) 
evolocumab and alirocumab, which have a mode of action complementary to statin and 
ezetimibe. 
Two large-scale randomized cardiovascular outcomes trials with these agents have recently 
been published: FOURIER (Further cardiovascular OUtcomes Research with PCSK9 
Inhibition in subjects with Elevated Risk) with evolocumab [50] and ODYSSEY 
OUTCOMES with alirocumab [51]. Both trials enrolled high-risk groups with established 
ASCVD and LDL-C levels ≥ 70 mg/dL on optimal statin therapy [50,51]. Ezetimibe was used 
infrequently at baseline (3–5% of patients in both trials). The study design of the two trials is 
shown in Table 2. In the FOURIER trial, 27 564 patients with stable ASCVD were 
randomized to double-blinded subcutaneous injections of evolocumab (either 140 mg every 2 
weeks or 420 mg monthly) or placebo [50]. In the ODYSSEY Outcomes trial, 18 924 early 
post-ACS patients were randomized to twice monthly injections of alirocumab (75 or 150 mg) 
or placebo [51]. Median baseline LDL-C levels in both trials were similar (92 mg/dL in 
FOURIER and 87 mg/dL in ODYSSEY OUTCOMES), and in both trials a reduction of at 
least 50% in LDL-C levels was achieved [50,51].  
The FOURIER primary composite endpoint was incidence of cardiovascular death, non-fatal 
MI, non-fatal stroke, hospitalization for unstable angina, or coronary revascularization, and 
occurred in 9.8% of the evolocumab group and 11.3% of the placebo group over a median 
follow-up of 2.2 years, a 15% reduction (P < 0.001) [50]. There was also a statistically 
significant 20% reduction in the key secondary endpoint, a composite of cardiovascular death, 
 
 
myocardial infarction, or stroke, which occurred in 5.9% and 7.4% of patients in the 
evolocumab and placebo groups, respectively (P < 0.001). No significant differences were 
observed in the risk of cardiovascular or all-cause mortality, but the study was not designed to 
detect such a difference and follow-up was relatively short [50]. 
The ODYSSEY OUTCOMES primary endpoint was a composite of death from CHD, 
nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina and 
occurred in 9.5% patients in the alirocumab group and 11.1% in the placebo group (P < 
0.001), a 15% reduction over a median follow-up of 2.8 years [51]. In this trial, all compo-
nents of the primary endpoint were significantly reduced except death by CHD. In both 
studies, the PCSK-9 inhibitors were well tolerated with no adverse safety concerns even 
among individuals who achieved very low LDL-C levels [51].   
Despite some differences in the design of the two trials (stable ASCVD, 80% of patients with 
previous MI, and single evolocumab dose in FOURIER, versus early post-ACS, 19% of 
patients with previous MI, and two doses of alirocumab in ODYSSEY OUTCOMES), both 
trials confirmed there is no LDL-C threshold for clinical benefit [50,51]. 
The addition of the PCSK-9 inhibitors to the lipid-lowering armamentarium provides an 
alternative, complementary, and aggressive mechanism of action for lipid lowering that will 
modify the share of other LDL-lowering agents on the market. Following the publication of 
results from the ezetimibe and PCSK-9 inhibitor cardiovascular outcome trials, European and 
US society task forces were convened to develop clinical guidance on when to use these non-
statin therapies, including in which patients, in which situations, and in which order [2,52]. In 
patients with clinical ASCVD, the recommended first approach to the management of 
elevated LDL-C levels was to intensify statin therapy. Based on the benefits on ASCVD 
outcomes and demonstrated safety of ezetimibe in patients with ACS in IMPROVE-IT, 
ezetimibe 10 mg was recommended as the first non-statin agent to be added. However, it was 
 
 
recognized that while the addition of ezetimibe provides a further reduction in LDL-C levels, 
this may not be sufficient to achieve the ≥ 50% reduction in LDL-C levels required by very 
high risk ASCVD patients to attain treatment goals. In these patients, further lipid lowering 
with the addition of a PCSK-9 inhibitor may be required.  
These recommendations have subsequently been incorporated into respective ESC/EAS and 
ACC cholesterol-lowering guidelines [3,8], both of which stratify patients by level of CVD 
risk. First-line therapy is with a high potency statin at the highest recommended/tolerable dose 
to reach the LDL-C goal. If the target is not achieved after 4–6 weeks despite lifestyle 
modification and maximally tolerated statin therapy, add-on therapy with ezetimibe and 
thereafter a PCSK-9 inhibitor is recommended. For secondary prevention in patients at very 
high CVD risk, ESC/EAS 2019 guidelines recommend lowering LDL-C to < 1.4 mmol/L (55 
mg/dL) and an LDL-C reduction of ≥ 50% from baseline [3]. PCSK-9 inhibitor use should be 
considered in patients with clinical ASCVD treated with maximal tolerated statin therapy 
and/or ezetimibe, but still showing LDL-C > 3.6 mmol/L (140 mg/dL). US ACC guidelines 
also recommend a ≥ 50% reduction from baseline, but have an LDL-C threshold of 1.8 
mmol/L (70 mg/dL) for the addition of a non-statin medication, first ezetimibe and then 
PCSK-9 inhibitors if LDL-C remains ≥ 70 mg/dL [8].  
Prescriptive barriers and possible solutions 
First approved for the management of cholesterol levels in patients with homozygous familial 
hypercholesterolemia, the EMA extended the indication for PCSK-9 inhibitors in 2018 to 
include secondary prevention in the high-risk group of patients with ASCVD. The latter in 
association with a statin at maximal tolerated dose with or without other lipid-lowering 
agents, or as monotherapy or in association with other non-statin therapies in patients 
intolerant of statins or in whom statins are contraindicated. However, the high cost of these 
medications has meant that they are not available for secondary prevention in all member 
 
 
states, and others regulatory authorities in other countries have defined criteria for their use in 
clinical practice.  
An analysis of a prospective Swiss cohort of 2023 patients hospitalized for ACS with 
available data for LDL-C and lipid-lowering therapy illustrated how different guideline 
criteria are able to influence the proportion of individuals eligible for treatment [53]. In the 
United States, the 2016 ACC expert consensus threshold for consideration of therapy with 
PCSK-9 inhibitors was 2.6 mmol/L versus 3.6 mmol/L in the ESC/EAS statement, with an 
even lower LDL‐C threshold (1.8 mmol/L) among patients with comorbidities or rapidly 
progressive ASCVD. In the Swiss cohort analysis, the use of a statin was 98.5% at discharge 
and 94.3% at 1 year. After modelling, the effect of ezetimibe in all patients not already 
receiving ezetimibe at 1 year, 13.4% would have been eligible for PCSK-9 inhibitors 
according to ACC guidelines, but only 2.7% of patients according to ESC/EAS guidelines 
[53]. 
A separate analysis considered PCSK-9 eligibility according to ESC/EAS and Agenzia 
Italiana del Farmaco (AIFA) regulatory agency criteria using data from two Italian, 
nationwide, prospective, real-world registries of patients with stable CAD [54]. Similar to the 
ACC, AIFA criteria consider post-MI patients eligible for PCSK-9 inhibitors if they have 
LDL-C > 100 mg/dL despite treatment with high potency statins plus ezetimibe, or ezetimibe 
alone in the presence of a well-documented condition of statin intolerance. Despite ESC/EAS 
guideline recommendations to treat LDL-C in post-MI patients to a target level of < 70 mg/dL 
using high-intensity statin therapy in combination with ezetimibe, if needed, the analysis 
revealed that many patients were undertreated with conventional lipid-lowering therapies 
[54]. A low-dose statin was prescribed in 9.3% of patients, and a high dose in 61.4%; statin 
plus ezetimibe therapy was used in less than 18% of cases. In the 3 074 post-MI patients with 
LDL-C data available, a target level of < 70 mg/dL was achieved in only 1186 (38.6%) 
 
 
patients and around a quarter (24%) had an LDL-C ≥ 100 mg/dL. Statins were prescribed to 
97.1% of patients with LDL-C levels < 70 mg/dL, 96.2% of those with LDL-C in the range 70 
to 99 mg/dL, and 90.8% in those with LDL-C levels ≥ 100 mg/dL. In the overall post-MI 
cohort treated with statins and/or ezetimibe (n=2 977), 293 (9.8%) and 450 (22.2%) would 
have been eligible for PCSK-9 inhibitors, according to ESC/EAS and AIFA criteria, 
respectively [54]. 
While ESC/EAS recommendations are more conservative than those of the ACC or AIFA, 
there must be a balance between setting levels too high that exclude a significant proportion 
of very high-risk patients that would gain clinical benefit from PCSK-9 inhibitors, and lower 
levels that are not sustainable for healthcare systems. Standard practice in ACS management 
is the initiation of a high-intensity statin during the acute phase, which is a particularly high-
risk period for recurrent events. This practice has a Class IA recommendation in the 
guidelines based on published evidence that it results in a significantly reduced rate of the 
composite of death, MI, or rehospitalization for ACS within 30 days, compared with a less 
aggressive approach to LDL cholesterol lowering [3].  
A small-scale trial has recently evaluated the benefit of the PCSK-9 inhibitors in this high-risk 
patient group. EVOPACS (Evolocumab for Early Reduction of LDL Cholesterol Levels in 
Patients With Acute Coronary Syndromes) randomized 308 patients hospitalized for ACS 
with elevated LDL-C levels to evolocumab 420 mg (n=155) or placebo (n=153) initiated in 
hospital and then every 4 weeks [55]. All patients received atorvastatin 40 mg and most 
patients (78.2%) had not been on statin treatment previously. At 8 weeks, mean LDL-C levels 
had decreased from 3.6 mmol/L (140 mg/dL) to 0.8 mmol/L (31 mg/dL) with evolocumab 
and from 3.4 mmol/L (132 mg/dL) to 2.1 mmol/L (80 mg/dL) with placebo. LDL-C levels < 
1.8 mmol/L were achieved at week 8 by 96% of patients in the atorvastatin/evolocumab group 
versus 38% of those on high-intensity statin plus placebo injection. Furthermore, 90% of the 
 
 
dual-therapy group had achieved the new ESC/EAS guideline-recommended target of an 
LDL-C level < 55 mg/dL, compared with 11% of patients randomized to high-intensity 
atorvastatin at 40 mg/day plus placebo injections [55]. 
The EVOPACS findings highlight the importance of starting early aggressive lipid-lowering 
therapy for rapid reductions in LDL-C in very high-risk patients. The clinical impact of very 
early LDL-C lowering with PCSK-9 inhibitors initiated in the acute ACS setting now 
warrants further investigation in a dedicated cardiovascular outcomes trial. The results of such 
a trial may help further define the population of high-risk patients who would benefit from the 
addition of PCSK-9 inhibitors to high-intensity statins and ezetimibe. 
Final considerations 
Dyslipidemia continues to be a central and modifiable causal risk factor in the development of 
ASCVD, and a major focus of intervention remains lowering plasma LDL-C levels, foremost 
with the use of high-intensity statins with the aim of reducing LDL-C by at least 50%. Current 
cholesterol guidelines have lowered LDL-C goals in patients at high ASCVD risk, but recent 
real-world data show that only a minority of patients using lipid-lowering drugs reach 
desirable LDL-C levels (< 70 mg/dL) [21,56,57]. 
When treating patients with high cholesterol, a one size fits all approach is not appropriate. 
When evaluating patients in clinic, there are two main groups of secondary prevention 
patients for whom the addition of ezetimibe and subsequently a PCSK-9 inhibitor to 
maximally tolerated statin may be appropriate. The first comprises patients with ASCVD and 
above goal LDL-C levels despite treatment with maximally tolerated statin, particularly if 
they have experienced recurrent events, and the second group comprises those who are statin 
intolerant, in whom the addition of ezetimibe and or a PCSK9-inhibitor may allow a lower 
statin dose to be used. In both instances the first non-statin therapy to be added should be 
ezetimibe from both an economical perspective and because the PCSK-9 inhibitors have not 
 
 
been evaluated in any ongoing trial without patients being on maximally tolerated statins or 
maximally tolerated statin plus ezetimibe. Coadministration of ezetimibe with the starting 
dose (10 mg) of atorvastatin has been shown to provide a 50% reduction in LDL-C, 
comparable to the 51% reduction obtained with high-dose (80 mg) atorvastatin [58]. In 
clinical practice, ezetimibe co-administered with maximally tolerated statin may enable more 
patients to achieve recommended target LDL-C levels by offering greater LDL-C lowering 
with fewer dose titrations as well as a well-tolerated alternative for patients in whom maximal 
dose statin monotherapy is inadequate.  
The PCSK-9 inhibitors lower LDL-C by 55% to 60% whether as monotherapy or when added 
to other lipid-lowering therapy. When used in combination, the LDL-C reductions are 
additive and therefore much greater lipid-lowering is achieved. As the tolerability profile of 
ezetimibe and the PCSK-9 inhibitors in combination with a statin is similar to statin 
monotherapy and as no study has yet lowered LDL-C levels to a point where they are 
harmful, current recommendations advocate their use in combination beginning with the 
addition of ezetimibe to maximally tolerated statin, and followed by the addition of a PCSK-9 
inhibitor. The eligibility for PCSK-9 inhibitors depends strongly on pre-treatment with 
ezetimibe in combination with a maximally tolerated statin. For maximum benefit, the 
addition of ezetimibe should be initiated early, particularly for patients at very high risk in 
whom a statin/ezetimibe combination should ideally be prescribed during the index 
hospitalization to allow rapid attainment of LDL-C targets and early prescription of PCSK-9 
inhibitors if required. 
Despite the efficacy of the above treatments, their benefits will only be replicated in real-life 
if patients adhere and comply with the prescribed treatment regimen. In this light, it is 
recognized that the real-life effectiveness of the statins is significantly compromised by poor 
adherence and compliance [59]. To improve patient adherence, SPC of ezetimibe and some 
 
 
statins are available. Ezetimibe has an acceptable and well-established tolerability profile over 
many years of clinical use. In addition, its use in combination with a statin may allow a 
reduction in statin dose.   
The decision to add non-statin lipid-lowering agents in the clinic is strongly dependent on 
costs versus health benefits. The costs of any new drug that reaches the market are likely to be 
high, and therefore efforts to individualize cardiovascular care are essential so that treatments 
reach those most in need and who will have the greatest benefit. As the statins and ezetimibe 
are available as generic treatments, a regimen of intense statin therapy with ezetimibe in all 
ASCVD patients should be implemented wherever possible. In some very high-risk patients 
such as those in EVOPACS this may still be insufficient, and the addition of a PCSK-9 
inhibitor may be required. Recent price reductions of the PCSK-9 inhibitors combined with 
targeting higher risk groups would limit the number of patients eligible for therapy and 
improve the economic impact of adopting these new therapies.   
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Table 1. Mean percent change of total cholesterol and LDL-C from untreated baseline of the 
single-pill combination of ezetimibe/simvastatin, ezetimibe/atorvastatin and 
ezetimibe/rosuvastatin in patients with primary hypercholesterolemia. 
 
 
Treatment N Total-C LDL-C 
Ezetimibe/simvastatin 
Pooled data (all ezetimibe/simvastatin doses) 609 -38 -53 
Pooled data (all simvastatin doses) 622 -28 -39 
Ezetimibe/simvastatin by dose 
    10/10 
    10/20 
    10/40 
    10/80 
 
152 
156 
147 
154 
 
-31 
-36 
-39 
-43 
 
-45 
-52 
-55 
-60 
Simvastatin by dose 
    10 
    20 
    40 
    80 
 
158 
150 
156 
158 
 
-23 
-24 
-29 
-35 
 
-33 
-34 
-41 
-49 
Ezetimibe/atorvastatin 
Pooled data (all ezetimibe/atorvastatin doses) 255 -41 -56 
Pooled data (all atorvastatin doses) 248 -32 -44 
Ezetimibe/atorvastatin by dose 
    10/10 
    10/20 
    10/40 
    10/80 
 
65 
62 
65 
63 
 
-38 
-39 
-42 
-46 
 
-53 
-54 
-56 
-61 
Atorvastatin by dose 
    10 
    20 
    40 
    80 
 
60 
60 
66 
62 
 
-26 
-30 
-32 
-40 
 
-37 
-42 
-45 
-54 
Ezetimibe/rosuvastatin 
Pooled data (all ezetimibe/ rosuvastatin doses) 195 -39 -57 
Pooled data (all rosuvastatin doses) 194 -30 -44 
Ezetimibe/rosuvastatin by dose 
    10/5 
    10/10 
    10/20 
 
65 
66 
64 
 
-35 
-39 
-45 
 
-52 
-57 
-64 
Rosuvastatin by dose 
    5 
    10 
    20 
 
65 
65 
64 
 
-29 
-31 
-35 
 
-40 
-46 
-49 
 
.  
 
 
 
Table 2. FOURIER and ODYSSEY OUTCOMES study design. 
 FOURIER ODYSSEY OUTCOMES 
Enrolled population (N) 27 564 18 924 
Age entry criteria (years) ≥40 and 85 ≥40  
Inclusion criteria Prior MI, stroke or 
symptomatic PAD plus 
additional high-risk features 
Prior ACS (between 1 and 
12 months) 
Lipid entry criteria LDL-C ≥70 mg/dL or non-
HDL-C ≥100 mg/dL 
LDL-C ≥70 mg/dL or non-
HDL-C ≥100 mg/dL or 
ApoB ≥80 mg/dL 
Primary endpoint CV death, fatal and non-fatal 
MI, stroke (all), unstable 
angina or coronary 
revascularization 
CHD death, non-fatal MI, 
unstable angina or stroke 
(ischemic) 
Therapy down-titration 
when LDL-C low 
No Yes 
 
ACS, acute coronary syndrome. ApoB, apolipoprotein B. CHD, coronary heart disease. CV, 
cardiovascular. HDL-C, high-density lipoprotein cholesterol. LDL-C, low-density lipoprotein 
cholesterol. MI, myocardial infarction. PAD, peripheral artery disease. 
 
  
 
 
 
Figure 1. Lipid-lowering mechanisms of action for statins, ezetimibe, and PCSK-9 inhibtors. 
 
 
 
